PDCD1 and acute myeloid leukemia: Consequently, PD-1/PD-L1/PD-L2 inhibitors—known as checkpoint inhibitors—have shown substantial efficacy in treating Hodgkin’s lymphoma, although their impact in AML treatment was considerably lower [109,110].